Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
TellBio, Inc. logo — Freeing patients from the tyranny of cancer™

TellBio, Inc.

Freeing patients from the tyranny of cancer™

Founded 2019 United States Andover, United States 5 employees Series A Total: $6.48M Biotechnology, Health Care

General Information

Company Name TellBio, Inc.
Founded Year 2019
Location United States Andover, United States
Employees 5
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, Platform, B2B2C
Revenue Model Product Sales, Licensing, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with TellBio, Inc.. To contact TellBio, Inc., visit tellbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TellBio, Inc. compare?

A PDF of TellBio, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TellBio, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TellBio, Inc.

TellBio, Inc., founded in 2019, is a forward-thinking biotechnology company headquartered in the United States. With a bold vision encapsulated in its slogan, “Freeing patients from the tyranny of cancer™,” TellBio is poised to revolutionize cancer diagnostics and treatment.

The company is developing two key platforms: TellDx and TellRx. TellDx is a diagnostic technology designed to detect live circulating tumor cells (CTCs) from liquid biopsies, offering a novel approach to cancer detection. Meanwhile, TellRx focuses on creating therapeutics that target CTCs, thereby potentially improving patient outcomes. Both platforms are built on proprietary technology exclusively licensed from Massachusetts General Hospital.

In its most recent funding round, the company secured a $5.00M Series A investment on 16 March 2021, backed by notable investors such as Genetron Health, ARUP Laboratories, Crocker Ventures, and the National Foundation for Cancer Research. As a development-stage company, TellBio represents a compelling opportunity for investors interested in cutting-edge healthcare solutions.

Services & Products

CTC isolation and detection
Cancer diagnostics
Anti-cancer drug development
Clinical research partnerships

Target Customers

cancer patients oncologists research institutions pharmaceutical companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $5.00M 4
Genetron Health
Genetron Health, ARUP Laboratories +2
16 Mar 2021
Venture Round $1.48M -
10 Oct 2019

TellBio, Inc. Alternatives & Competitors

View All Alternatives
TellBio, Inc. vs
IV Diagnostics
IV Diagnostics

Advancing Early Cancer Detection with Circulating Tumor Cells for Improved Prognosis and Disease Man...

Private Equity
Biotechnology, Health Care
TellBio, Inc. vs
Cellsway
Cellsway United Kingdom

Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) fr...

5 employees
Biotechnology, Health Care
TellBio, Inc. vs
On-Q-ity
On-Q-ity

Empowering physicians with advanced tools to improve cancer treatment decisions and enhance patient...

Series B
Biotechnology, Health Care
Also compare with: TellBio, Inc. vs Vortex Biosciences Vortex Biosciences View all alternatives

FAQ About TellBio, Inc.

Freeing patients from the tyranny of cancer™
TellBio, Inc. was founded in 2019.
TellBio, Inc. is headquartered in Andover, United States.
TellBio, Inc. operates in Biotechnology and Health Care. Its customers include cancer patients, oncologists and research institutions.
TellBio, Inc. has a B2B, Platform and B2B2C business model. Its revenue comes from Product Sales, Licensing and Usage Based.
TellBio, Inc. has approximately 5 employees.
TellBio, Inc. has completed 2 funding rounds, raising a total of $6.48M. The latest funding stage is Series A.
TellBio, Inc. offers: CTC isolation and detection, Cancer diagnostics, Anti-cancer drug development, Clinical research partnerships.
Top alternatives and competitors to TellBio, Inc. include IV Diagnostics, Cellsway, On-Q-ity, Kintara Therapeutics, Inc. NASDAQ: KTRA, Vortex Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TellBio, Inc. and IV Diagnostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TellBio, Inc., https://bouncewatch.com/company/tellbio-inc, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout